B
Bérengère Aubry-Rozier
Researcher at University of Lausanne
Publications - 102
Citations - 2546
Bérengère Aubry-Rozier is an academic researcher from University of Lausanne. The author has contributed to research in topics: Osteoporosis & Trabecular bone score. The author has an hindex of 22, co-authored 97 publications receiving 2032 citations. Previous affiliations of Bérengère Aubry-Rozier include University Hospital of Lausanne.
Papers
More filters
Journal ArticleDOI
Discontinuation of Denosumab therapy for osteoporosis: A systematic review and position statement by ECTS.
Elena Tsourdi,Bente L. Langdahl,Martine Cohen-Solal,Bérengère Aubry-Rozier,Erik Fink Eriksen,Núria Guañabens,Barbara Obermayer-Pietsch,Stuart H. Ralston,Richard Eastell,M. Carola Zillikens +9 more
TL;DR: There appears to be an increased risk of multiple vertebral fractures after discontinuation of denosumab although strong evidence for such an effect and for measures to prevent the occurring bone loss is lacking.
Journal ArticleDOI
TBS (trabecular bone score) and diabetes-related fracture risk.
TL;DR: Lumbar spine TBS predicts osteoporotic fractures in those with diabetes, and captures a larger portion of the diabetes-associated fracture risk than BMD.
Journal ArticleDOI
Clinical Features of 24 Patients With Rebound-Associated Vertebral Fractures After Denosumab Discontinuation: Systematic Review and Additional Cases.
Athanasios D. Anastasilakis,Stergios A. Polyzos,Polyzois Makras,Bérengère Aubry-Rozier,Stella Kaouri,Olivier Lamy +5 more
TL;DR: It is concluded that vertebral fracture(s) after denosumab discontinuation are in the majority of patients multiples, and they occur a few months after the effect of the last dose is depleted, therefore, patients should not delay or omit denOSumab doses.
Journal ArticleDOI
Severe Rebound-Associated Vertebral Fractures After Denosumab Discontinuation: 9 Clinical Cases Report.
TL;DR: It is hypothesized that the severe BTR is involved in microdamage accumulation in trabecular bone and thus promotes VFs, and studies are urgently needed to determine the pathophysiological processes involved, the clinical profile of patients at risk for RAVFs and the management and/or treatment regimens after denosumab discontinuation.
Journal ArticleDOI
Severe spontaneous vertebral fractures after denosumab discontinuation: three case reports.
TL;DR: It is thought that the occurrence of these fractures could be explained by the severe rebound effect observed after denosumab discontinuation and that a consensus regarding the end of treatment with denosUMab has to be defined.